Angiotensin-receptor blockers for renal protection in Type 2 diabetes

Piero Ruggenenti, Manuel Marcia, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review


Diabetic nephropathy is the single most frequent cause of end-stage renal disease worldwide. Diabetic nephropathy is characterized by proteinuria, gradual loss of renal function, hypertension and increased cardiovascular risk. In Type 2 diabetes mellitus, the disease is often detected when nephropathy has already progressed to advanced stages that only marginally benefit from renoprotective treatments. Thus, screening programs are needed to detect diabetic nephropathy and initiate treatment before progression becomes irreversible. The renin-angiotensin system is often activated in diabetic nephropathy and may contribute to the progression of renal injury through a variety of mechanisms largely mediated by the angiotensin type 1 receptor. Renin-angiotensin system inhibition, in particular by angiotensin-receptor blockers, may have specific cardiovascular and renoprotective effects that are at least in part independent of blood pressure reduction, and may also improve several features of the metabolic syndrome that almost invariably accompany the disease. Whether combined therapy with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers may offer additional benefits compared with angiotensin-receptor blocker therapy alone is still under investigation.

Original languageEnglish
Pages (from-to)295-301
Number of pages7
JournalAging Health
Issue number2
Publication statusPublished - Apr 2006


  • Angiotensin-receptor blockrers
  • Candesartan
  • Diabetic nephropathy
  • Irbersartan
  • Losartan
  • Microalbuminuria
  • Renin-angiotensin system
  • Telmisartan
  • Valsartan

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)


Dive into the research topics of 'Angiotensin-receptor blockers for renal protection in Type 2 diabetes'. Together they form a unique fingerprint.

Cite this